Free Design Audit Available - Click Here for Details

Abbott wins FDA approval for dissolving drug-eluting scaffold

Abbott (NYSE: ABT)+ announced today that the FDA approved its Esprit everolimus-eluting resorbable scaffold system.

The Esprit scaffold treats chronic limb-threatening ischemia (CLTI) below the knee (BTK). Abbott designed it to keep arteries open and deliver everolimus to support vessel healing prior to completely dissolving.

Abbott says that before this approval, there were no stents or drug-coated balloons to treat below-the-knee chronic limb-threatening ischemia in the U.S.

The current standard of care, balloon angioplasty, relies on a small balloon delivered via a catheter. It compresses against the arterial wall, opening the blood vessel and restoring flow

Sign up for Blog Updates